This observational survey study (n=752.374) investigated the relationship between lifetime classic psychedelic use and cardiometabolic diseases and found that lifetime classic psychedelic use was associated with a 23% lower odds of heart disease and a 12% lower odds of diabetes in the past year.
“Introduction: The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases.
Methods: Using data from the National Survey on Drug Use and Health (2005-2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes.
Results: Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65-0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78-0.99), p = .036).
Discussion: Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.”
Authors: Otto Simonsson, Walter Osika, Robin L. Carhart-Harris & Peter S. Hendricks
Find this paper
July 13, 2021
Authors associated with this publication with profiles on BlossomRobin Carhart-Harris
Dr. Robin Carhart-Harris is the Founding Director of the Neuroscape Psychedelics Division at UCSF. Previously he led the Psychedelic group at Imperial College London.